The anxiolytic- and antidepressant-like effects of ATPM-ET, a novel κ agonist and μ partial agonist, in mice

Psychopharmacology (Berl). 2016 Jun;233(12):2411-8. doi: 10.1007/s00213-016-4292-z. Epub 2016 Apr 26.

Abstract

Rationale: Opioid receptors are implicated in the regulation of motivation and emotion. However, animal studies show that activation of κ opioid receptor produces contrasting mood-altering effects in models of anxiety-like and depressive-like behaviors, and consequently, the role of κ receptor in mood control remains unsettled. The effect of κ/μ opioid combination in emotion regulation was unexplored.

Objectives: The aim of the study was to investigate the effects of (-)-3-N-ethylaminothiazolo [5,4-b]-N-cyclopropylmethylmorphinan hydrochloride (ATPM-ET), a novel κ agonist and μ partial agonist, in regulating emotional responses.

Methods: The emotional responses of ATPM-ET were detected in the elevated plus maze (EPM), open field test (OFT), forced swim test (FST), and tail suspension test (TST). Selective κ antagonist nor-binaltorphimine (nor-BNI) and μ antagonist β-funaltrexamine (β-FNA) were applied to determine the type of receptor involved. The conditioned place aversion model was used to evaluate the effects on aversive emotion.

Results: In the EPM and OFT, ATPM-ET (1 and 2 mg/kg, s.c.) significantly increased the time spent in the open arm and in the central area, respectively. In the FST and TST, ATPM-ET (0.5 and 1 mg/kg, s.c.) significantly reduced the duration of immobility. These effects were prevented by nor-BNI (10 mg/kg, i.p., -24 h), but not by β-FNA (10 and20 mg/kg, i.p., -24 h) pretreatment. At the dose of 2 mg/kg, ATPM-ET did not induce conditioned place aversion.

Conclusions: ATPM-ET, at doses from 0.5 to 2 mg/kg, produced anxiolytic- and antidepressant-like effects without inducing aversive emotion. These effects were more closely mediated by activation of κ receptor than μ receptor.

Keywords: ATPM-ET; Emotional response; κ agonist; μ partial agonist.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Anxiety Agents / pharmacology*
  • Antidepressive Agents / pharmacology*
  • Anxiety / drug therapy
  • Anxiety / psychology
  • Avoidance Learning / drug effects
  • Emotions / drug effects
  • Exploratory Behavior / drug effects
  • Hindlimb Suspension / psychology
  • Locomotion / drug effects
  • Mice
  • Morphinans / pharmacology*
  • Naltrexone / analogs & derivatives
  • Naltrexone / pharmacology
  • Receptors, Opioid, kappa / agonists*
  • Receptors, Opioid, kappa / antagonists & inhibitors
  • Receptors, Opioid, mu / agonists*
  • Receptors, Opioid, mu / antagonists & inhibitors

Substances

  • 3-N-ethylaminothiazolo(5,4-b)-N-cyclopropylmethylmorphinan hydrochloride
  • Anti-Anxiety Agents
  • Antidepressive Agents
  • Morphinans
  • Receptors, Opioid, kappa
  • Receptors, Opioid, mu
  • norbinaltorphimine
  • Naltrexone
  • beta-funaltrexamine